AIMS: Adherence to the generally complex regimen of coumarin derivatives is vital in order to keep patients in the adequate International Normalized Ratio range. Patients' beliefs about medicines are associated with the level of therapy adherence. Our first aim was to assess beliefs about coumarins. Secondly, we compared the beliefs about coumarins with the beliefs about other cardiovascular drugs. METHODS: The Beliefs about Medicines Questionnaire was used to assess medication beliefs. The questionnaire was completed by new users of coumarins indicated for venous thromboembolism or atrial fibrillation. A necessity score and a concerns score were calculated for all patients. The analyses were repeated for users of antihypertensive drugs or statins (not using coumarins). RESULTS: Three hundred and twenty patients were included in the analysis of the beliefs about coumarins. The mean necessity score was 15.3, the concerns score 12.3 and the necessity-concerns differential 3.0. Patients with venous thromboembolism (n = 71) had higher necessity scores than patients with atrial fibrillation (n = 249; 16.8 vs. 14.9, P < 0.001). The mean necessity score in 493 users of other cardiovascular drugs was 16.1, the concerns score 13.5 and the necessity-concerns differential 2.6. The necessity score was higher in chronic cardiovascular drug users (n = 192) than in new users (n = 301; 17.9 vs. 14.9, P < 0.001). CONCLUSIONS: Coumarin users score higher on the necessity scale than on the concerns scale, which is also the case in users of other cardiovascular drugs. Patients with atrial fibrillation have a less positive attitude towards these drugs than patients with venous thromboembolism, and could therefore benefit more from specific attention.
AIMS: Adherence to the generally complex regimen of coumarin derivatives is vital in order to keep patients in the adequate International Normalized Ratio range. Patients' beliefs about medicines are associated with the level of therapy adherence. Our first aim was to assess beliefs about coumarins. Secondly, we compared the beliefs about coumarins with the beliefs about other cardiovascular drugs. METHODS: The Beliefs about Medicines Questionnaire was used to assess medication beliefs. The questionnaire was completed by new users of coumarins indicated for venous thromboembolism or atrial fibrillation. A necessity score and a concerns score were calculated for all patients. The analyses were repeated for users of antihypertensive drugs or statins (not using coumarins). RESULTS: Three hundred and twenty patients were included in the analysis of the beliefs about coumarins. The mean necessity score was 15.3, the concerns score 12.3 and the necessity-concerns differential 3.0. Patients with venous thromboembolism (n = 71) had higher necessity scores than patients with atrial fibrillation (n = 249; 16.8 vs. 14.9, P < 0.001). The mean necessity score in 493 users of other cardiovascular drugs was 16.1, the concerns score 13.5 and the necessity-concerns differential 2.6. The necessity score was higher in chronic cardiovascular drug users (n = 192) than in new users (n = 301; 17.9 vs. 14.9, P < 0.001). CONCLUSIONS:Coumarin users score higher on the necessity scale than on the concerns scale, which is also the case in users of other cardiovascular drugs. Patients with atrial fibrillation have a less positive attitude towards these drugs than patients with venous thromboembolism, and could therefore benefit more from specific attention.
Authors: Rianne M F van Schie; M I A Wadelius; Farhad Kamali; Ann K Daly; Vangelis G Manolopoulos; Anthonius de Boer; Rita Barallon; Talitha I Verhoef; Julia Kirchheiner; Elisabeth Haschke-Becher; Montserrat Briz; Frits R Rosendaal; William K Redekop; Munir Pirmohamed; Anke-Hilse Maitland van der Zee Journal: Pharmacogenomics Date: 2009-10 Impact factor: 2.533
Authors: Erica C G van Geffen; Daphne Philbert; Carla van Boheemen; Liset van Dijk; Marieke B Bos; Marcel L Bouvy Journal: Patient Educ Couns Date: 2011-05-06
Authors: James E Aikens; Donald E Nease; David P Nau; Michael S Klinkman; Thomas L Schwenk Journal: Ann Fam Med Date: 2005 Jan-Feb Impact factor: 5.166
Authors: Tanja T Menckeberg; Marcel L Bouvy; Madelon Bracke; Ad A Kaptein; Hubert G Leufkens; Jan A M Raaijmakers; Rob Horne Journal: J Psychosom Res Date: 2008-01 Impact factor: 3.006
Authors: Ujjaini Khanderia; Kevin A Townsend; Steven R Erickson; Jon Vlasnik; Richard L Prager; Kim A Eagle Journal: Ann Pharmacother Date: 2008-01-15 Impact factor: 3.154
Authors: Mark M T J Broekman; Marieke J H Coenen; Geert J Wanten; Corine J van Marrewijk; Wietske Kievit; Olaf H Klungel; André L M Verbeek; Dennis R Wong; Piet M Hooymans; Henk-Jan Guchelaar; Hans Scheffer; Luc J J Derijks; Marcel L Bouvy; Dirk J de Jong Journal: Eur J Gastroenterol Hepatol Date: 2018-02 Impact factor: 2.566
Authors: John K Bartoli-Abdou; Jignesh P Patel; Rosa Xie; Olubanke Dzahini; Bipin Vadher; Alison Brown; Lara N Roberts; Raj K Patel; Roopen Arya; Vivian Auyeung Journal: Res Pract Thromb Haemost Date: 2018-06-07